The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)

WITHDRAWN: Phase 3 study of zipalertinib plus adjuvant chemotherapy in early-stage NSCLC harboring EGFR exon 20 insertion or other uncommon EGFR mutations (REZILIENT4).

Jamie  Chaft

Consulting or Advisory Role - AstraZeneca/MedImmune; Boehringer Ingelheim; Exact Sciences; Foundation Medicine; Genentech/Roche; Lilly; Merck; Natera; Nuvation Bio; Revolution Medicines

Research Funding - AstraZeneca/MedImmune (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Lilly (Inst); Merck (Inst)

(OPTIONAL) Uncompensated Relationships - AstraZeneca; Boehringer Ingelheim; Lilly; Merck

Tae Min  Kim

Consulting or Advisory Role - Amgen; AstraZeneca/MedImmune; BeiGene; Chong Kun Dang Pharmaceutical; Daewoong Pharmaceutical; Daiichi Sankyo/Astra Zeneca; Janssen Oncology; Merck KGaA; Samsung Bioepis; Takeda

Speakers' Bureau - Amgen; AstraZeneca/MedImmune; BeiGene; Janssen Research & Development; Takeda

(OPTIONAL) Uncompensated Relationships - Abbvie (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); BeiGene (Inst); Black Diamond Therapeutics (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Boryung (Inst); Bristol Myers Squibb Foundation (Inst); Chimerix (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Dizal Pharma (Inst); Enliven Therapeutics (Inst); Fore Biotherapeutics (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Hanmi (Inst); IDEAYA Biosciences (Inst); Incyte (Inst); Janssen Oncology (Inst); Merck (Inst); Merck Serono (Inst); Novartis (Inst); RAPT Therapeutics (Inst); Regeneron (Inst); Roche/Genentech (Inst); Sanofi (Inst); SERVIER (Inst); Takeda (Inst); Yuhan (Inst)

Yasushi  Goto

Honoraria - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo/Astra Zeneca; Daiichi Sankyo/UCB Japan; Janssen; Lilly Japan; Merck; MSD; Nichiiko; Novartis; Ono Pharmaceutical; Pfizer; Sandoz; Taiho Pharmaceutical; Takeda; Thermo Fisher Scientific; Towa Pharmaceutical

Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo/UCB Japan; GlaxoSmithKline; Janssen; Jazz Pharmaceuticals; Kyowa Kirin International; Lilly; MSD; Novartis; Ono Pharmaceutical; Pfizer; Summit Health; Taiho Pharmaceutical

Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Amgen BioPharama (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); CMIC (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo/UCB Japan (Inst); EP Croit Co. (Inst); EPS Holdings (Inst); Genomic Health (Inst); IQvia (Inst); Janssen (Inst); Lilly Japan (Inst); Medpace (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Preferred Network (Inst); Sysmex (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)

(OPTIONAL) Uncompensated Relationships - Cancer Net Japan; JAMT

Sanjay  Popat

Consulting or Advisory Role - Amgen; Anheart Therapeutics; Arcus Biosciences; AstraZeneca; Bayer; Bicycle Therapeutics; BioNTech SE; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; Ellipses Pharma; Erasca, Inc; Genmab; Gilead Sciences; GlaxoSmithKline; Guardant Health; IO Biotech; Janssen; Lilly; Merck KGaA; MSD; Nuvalent, Inc.; Pfizer; Pfizer; PharmaMar; Pierre Fabre; Pierre Fabre; Roche; SERVIER; Summit Therapeutics; Taiho Oncology; Takeda

Research Funding - Amgen (Inst); ARIAD (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Clovis Oncology (Inst); Daiichi Sankyo (Inst); Epizyme (Inst); GlaxoSmithKline (Inst); Guardant Health (Inst); Janssen (Inst); Lilly (Inst); Mirati Therapeutics (Inst); MSD (Inst); Novartis (Inst); Roche (Inst); Takeda (Inst); Trizell (Inst); Turning Point Therapeutics (Inst)

Travel, Accommodations, Expenses - Gilead Sciences; Roche/Genentech

Alexander  Spira

Leadership - Next Oncology (Inst)

Honoraria - Abbvie; Abbvie; Abbvie; Amgen; Astellas Pharma; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; CytomX Therapeutics; Janssen Oncology; Lilly; Merck; Novartis; Prelude Therapeutics; Takeda

Consulting or Advisory Role - Amgen; ArriVent Biopharma; AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); Black Diamond Therapeutics; Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); crispr therapeutics; Daiichi Sankyo/Astra Zeneca; GlaxoSmithKline; Gritstone Bio; Gritstone Bio; incyte; Janssen Research & Development; Jazz Pharmaceuticals; Lilly; Merck (Inst); Mersana; Mirati Therapeutics; Novartis; Regeneron; Revolution Medicines; Sanofi; Sanofi; Synthekine; Takeda

Research Funding - Abbvie (Inst); ADC Therapeutics (Inst); ADC Therapeutics (Inst); Alkermes (Inst); Amgen (Inst); ArriVent Biopharma (Inst); Astellas Pharma (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Blueprint Medicines (Inst); BluPrint Oncology (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Gritstone Bio (Inst); Ignyta (Inst); Incyte (Inst); Janssen Oncology (Inst); LAM Therapeutics; lepu biopharma (Inst); Lilly (Inst); Loxo (Inst); Loxo (Inst); Macrogenics (Inst); Medikine (Inst); MedImmune (Inst); mersana (Inst); nalo therapeutics (Inst); Novartis (Inst); Plexxikon (Inst); Prelude Therapeutics (Inst); Regeneron (Inst); Revolution Medicines (Inst); Revolution Medicines (Inst); Roche (Inst); Rubius Therapeutics (Inst); Scorpion Therapeutics (Inst); Synthekine (Inst); Synthekine (Inst); Takeda (Inst); Tango Therapeutics (Inst)

Christina  Baik

Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol Myers Squibb Foundation; Daiichi Sankyo/UCB Japan; Genentech/Roche; Janssen; Lilly; Natera; Nuvalent, Inc.; Pfizer; Regeneron; Takeda

Research Funding - Abbvie (Inst); AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Blossom Hills (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol Myers Squibb Foundation (Inst); Daiichi Sankyo (Inst); Ellipses Pharma (Inst); Janssen (Inst); Lilly (Inst); Nuvalent, Inc. (Inst); Pfizer (Inst); Summit Therapeutics (Inst); Systimmune (Inst); TP Therapeutics (Inst)

Leah  Jin

Employment - Taiho Oncology

Bailey  Anderson

Employment - Taiho Oncology

Kazunobu  Kato

Employment - Bristol-Myers Squibb; Celgene; Daiichi Sankyo; Shattuck Labs; Taiho Oncology

Stock and Other Ownership Interests  - Bristol-Myers Squibb; Celgene; Shattuck Labs

Consulting or Advisory Role - Shattuck Labs

David  Planchard

Honoraria - Medscape; PeerVoice; Prime Oncology

Consulting or Advisory Role - Abbvie; ArriVent Biopharma; AstraZeneca; BeiGene; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Daiichi Sankyo/Astra Zeneca; Ellipses Pharma; Gilead Sciences; Janssen; MSD Oncology; Novartis; Pfizer; Pierre Fabre; Roche; Seagen

Research Funding - Abbvie (Inst); ArriVent Biopharma (Inst); AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Ellipses Pharma (Inst); Janssen (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Roche (Inst); Sanofi/Aventis (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst)